Suchergebnisse - "Smith, Patrick F"

PubPharm (18)

1

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor : Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

enthalten in: Clinical and translational science | 2023

von Ucpinar, S. | Smith, P. | Long, L. | +7

2

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection : Safety, efficacy, and pharmacokinetic results

enthalten in: PloS one | 2023

von Oey, A. | McClure, M. | Symons, J. | +13

3

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers : A phase I, randomized study

enthalten in: Clinical and translational science | 2022

von Kallend, D. | Mason, J. | Smith, P. | +4

4

A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects

enthalten in: Clinical and translational science | 2022

von Ucpinar, S. | Darpo, B. | Neale, A. | +8

5

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

enthalten in: Clinical and translational science | 2022

von Owens, T. | Smith, P. | Redfern, A. | +8

6

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

enthalten in: British journal of clinical pharmacology | 2017

von Smith, P. | Krishnarajah, J. | Nunn, P. | +6

7

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

enthalten in: EBioMedicine | 2016

von Wollacott, A. | Boni, M. | Szretter, K. | +8

CommentIn: EBioMedicine. 2016 Mar;5:16-7. - PMID 27077102

8

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV

enthalten in: Antiviral therapy | 2015

von Canini, L. | Chatterjee, A. | Guedj, J. | +4

9

Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy

enthalten in: Pharmacotherapy | 2014

von Moreira, S. | Morcos, P. | Navarro, M. | +3

10

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

enthalten in: European journal of clinical pharmacology | 2013

von Morcos, P. | Chang, L. | Kulkarni, R. | +5